Skip to Content
Morningstar

Pfizer Inc PFE

Morningstar Rating
Unlock
Stock XNYS Rating as of
$30.47 +0.39 (1.30%)
View Full Chart
As of Delayed Price Pre-Open: $30.50 0.00
Unlock Our Analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Pfizer Earnings: Expected COVID-19 Sales Decline Pressures Results, but Remaining Business Is Solid

Damien Conover

Pfizer reported third-quarter results largely in line with our expectations, and we are not making any changes to our fair value estimate. Results largely tracked Pfizer’s recently updated 2023 guidance that includes a major step down in COVID-19 vaccine (Comirnaty) and treatment (Paxlovid) sales. With the stock’s pull back from the peak of the pandemic, we believe the market is underappreciating the tail potential of Pfizer’s COVID-19 sales and next-generation drugs.

Read Full Report

Price vs Fair Value

View History
PFE is trading within a range we consider fairly valued.
Price
$30.47
Fair Value
$47.00
Uncertainty
Medium
1-Star Price
$15.50
5-Star Price
$56.40
Economic Moat
Djl
Capital Allocation
Xgxcyhgjm

Bulls Say, Bears Say

Bulls

Pfizer's pipeline productivity is improving with several successful recent drug launches. In particular, cardiovascular drug Vyndaqel is a potential game-changer in the rare-disease arena.

Bears

Past aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment into innovation.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PFE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$30.08
Day Range
$29.96–30.51
52-Week Range
$28.93–54.93
Bid/Ask
$30.46 / $30.53
Market Cap
$172.05 Bil
Volume/Avg
2,340 / 29.1 Mil

Key Statistics

Price/Earnings (Normalized)
10.62
Price/Sales
2.54
Dividend Yield
5.38%
Dividend Yield (Forward)
5.38%
Total Yield
5.38%

Company Profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
83,000
Website
https://www.pfizer.com

Competitors

Valuation

View More
Metric
PFE
LLY
MRK
Price/Earnings (Normalized)
 10.6299.8333.16
Price/Book Value
 1.7750.006.30
Price/Sales
 2.5416.654.40
Price/Cash Flow
 8.9377.9613.13
Price/Earnings
PFE
LLY
MRK

Financial Strength

Metric
PFE
LLY
MRK
Quick Ratio
 1.900.580.83
Current Ratio
 2.381.051.38
Interest Coverage
 6.0514.877.59
Quick Ratio
PFE
LLY
MRK

Profitability

Metric
PFE
LLY
MRK
Return on Assets (Normalized)
 8.04%10.19%7.38%
Return on Equity (Normalized)
 16.96%49.42%18.18%
Return on Invested Capital (Normalized)
 11.79%19.29%10.92%
Return on Assets
PFE
LLY
MRK

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
LLY
Eli Lilly and CoZvbd$561.1 Bil
JNJ
Johnson & JohnsonVhpdv$372.3 Bil
MRK
Merck & Co IncHjvgv$259.7 Bil
ABBV
AbbVie IncRkrkbc$251.4 Bil
RHHBY
Roche Holding AG ADRVxjv$217.5 Bil
NVS
Novartis AG ADRKrgq$200.3 Bil
AZN
AstraZeneca PLC ADRKqp$199.2 Bil
AMGN
Amgen IncHck$144.3 Bil
SNY
Sanofi SA ADRZgmvk$117.6 Bil